Phase III randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma

被引：15
|
作者：
Lian, Bin
Cui, Chuanliang
Song, Xin
Zhang, Xiaoshi
Wu, Di
Si, Lu
Chi, Zhihong
Sheng, Xinan
Kong, Yan
Mao, Li Li
Zhou, Li
Wang, Xuan
Tang, Bixia
Yan, Xieqiao
Li, Siming
Li, Dan
Dai, Jie
Bai, Xue
Li, CaiLi
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[3] Jilin Univ, Hosp 1, Jilin, Jilin, Peoples R China
[4] Beijing Canc Hosp, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Collaborat Innovat Ctr Canc Med, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
[6] Peking Univ Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9589
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
    Si, Lu
    Wang, Xuan
    Kong, Yan
    Lian, Bin
    Chi, Zhi Hong
    Cui, Chuan Liang
    Sheng, Xi Nan
    Mao, Li Li
    Tang, Bi Xia
    Li, Si Ming
    Yan, Qiao Xie
    Guo, Jun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects
    Rex, JH
    Pappas, PG
    Karchmer, AW
    Sobel, J
    Edwards, JE
    Hadley, S
    Brass, C
    Vazquez, JA
    Chapman, SW
    Horowitz, HW
    Zervos, M
    McKinsey, D
    Lee, J
    Babinchak, T
    Bradsher, RW
    Cleary, JD
    Cohen, DM
    Danziger, L
    Goldman, M
    Goodman, J
    Hilton, E
    Hyslop, NE
    Kett, DH
    Lutz, J
    Rubin, RH
    Scheld, WM
    Schuster, M
    Simmons, B
    Stein, DK
    Washburn, RG
    Mautner, L
    Chu, TC
    Panzer, H
    Rosenstein, RB
    Booth, J
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) : 1221 - 1228
  • [33] EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
    Eggermont, A. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C.
    Hauschild, A.
    Gore, M.
    Keilholz, U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [34] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Schadendorf, Dirk
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Anette
    Schneider, Lars
    Podda, Maurizio
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma
    Schmidt, Jan
    Abel, Ulrich
    Debus, Juergen
    Harig, Sabine
    Hoffmann, Katrin
    Herrmann, Thomas
    Bartsch, Detlef
    Klein, Justus
    Mansmann, Ulrich
    Jaeger, Dirk
    Capussotti, Lorenzo
    Kunz, Reiner
    Buechler, Markus W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (33) : 4077 - 4083
  • [36] A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
    Grignol, Valerie P.
    Olencki, Thomas
    Relekar, Kiran
    Taylor, Cynthia
    Kibler, Amanda
    Kefauver, Cheryl
    Wei, Lai
    Walker, Michael J.
    Chen, Helen X.
    Kendra, Kari
    Carson, William E., III
    [J]. JOURNAL OF IMMUNOTHERAPY, 2011, 34 (06) : 509 - 515
  • [37] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [38] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Alexander M. M. Eggermont
    Marna G. Bouwhuis
    Wim H. Kruit
    Alessandro Testori
    Timo ten Hagen
    Antoine Yver
    Christine Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 671 - 677
  • [39] A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-α2B in patients with metastatic melanoma
    Atkins, MB
    Gollob, JA
    Sosman, JA
    McDermott, DF
    Tutin, L
    Sorokin, P
    Parker, RA
    Mier, JW
    [J]. CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3075 - 3081
  • [40] Pharmacogenomics (PGX) research in the apex randomized multicenter international phase 3 trial comparing bortezomib and high-dose dexamethasone (DEX)
    Mulligan, G.
    Mitsiades, C.
    Bryant, B.
    Zhan, F.
    Cheng, W.
    Eschrich, S.
    Burrington, B.
    Richardson, P.
    Trepicchio, W.
    Shaughnessy, J.
    Bergsagel, L.
    Damokosh, A.
    Boral, A.
    Esseltine, D.
    Schenkein, D.
    Anderson, K.
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 81 - 82
12345